Back
Corporate News
Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for approximately Rs 9.12 crores
18-Aug-2026, 06:12
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced that its board approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately Rs 9.12 crores, subject to adjustment as per the share purchase agreement. IQGEN-X Pharma Private Limited, incorporated in October 2016, reported a turnover of Rs 348 lacs for the financial year ended March 31, 2026, and is engaged in the business of formulation development for regulated and semi-regulated markets, with the acquisition expected to provide Alivus Life Sciences a wider spectrum to offer end-to-end solutions in the API and CDMO space.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced that its board approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately Rs 9.12 crores, subject to adjustment as per the share purchase agreement. IQGEN-X Pharma Private Limited, incorporated in October 2016, reported a turnover of Rs 348 lacs for the financial year ended March 31, 2026, and is engaged in the business of formulation development for regulated and semi-regulated markets, with the acquisition expected to provide Alivus Life Sciences a wider spectrum to offer end-to-end solutions in the API and CDMO space.